1 Title

- 2 The concentration of tuberculosis within Paraguay's incarcerated and Indigenous populations,
- 3 2018-2022

4 Keywords

5 Tuberculosis, epidemiology, incarceration

6 Author list

- 7 Angélica Medina¹*, Jacob Sussman²*, Natalia Sosa¹, Melissa Valdez¹, Jason R. Andrews³, Julio
- 8 Croda^{4,5,6}, Gladys Estigarribia Sanabria⁷, Guillermo Sequera^{1,8#}, Sarita Aguirre^{1#}, Katharine S.
- 9 Walter^{2#}
- 10 * These authors contributed equally to this article.
- [#] These authors contributed equally to this article.

12 Affiliations

- 13 1. Programa Nacional de Control de la Tuberculosis, Asunción, Paraguay
- 14 2. University of Utah School of Medicine, Salt Lake City, Utah, USA
- 15 3. Stanford University School of Medicine, Stanford, California, USA
- 16 4. Federal University of Mato Grosso do Sul UFMS, Campo Grande, MS, Brazil
- 17 5. Oswaldo Cruz Foundation Mato Grosso do Sul, Mato Grosso do Sul, Brazil
- 18 6. Yale School of Public Health, New Haven, Connecticut, USA
- 19 7. Instituto Regional de Investigación en Salud, Caaguazú, Paraguay
- 20 8. Instituto de Salud Global de Barcelona (ISGLOBAL), Barcelona, Spain
- 21 Address for correspondence: Katharine S. Walter, Division of Epidemiology, University of Utah
- 22 School of Medicine, 295 Chipeta Way, Salt Lake City, UT 84108, (801) 585-6667; email:
- 23 Katharine.Walter@hsc.utah.edu

24 Abstract

25 While incidence of tuberculosis (TB) has decreased globally, in Paraguay, considered a 26 medium-incidence country by the WHO, TB incidence has increased slightly from 42 per 27 100,000 in 2010 to 46 per 100,000 in 2022. We conducted a retrospective study of TB cases 28 notified to the Paraguay National Program for Tuberculosis Control (NPTC) from 2018 to 2022 29 and quantified trends in specific populations identified as vulnerable. Of the 13,725 TB cases 30 notified in Paraguay from 2018 to 2022, 2,331 (17%) occurred among incarcerated individuals 31 and 1,743 (12.7%) occurred among self-identified Indigenous individuals. In 2022, the relative 32 risk of TB was 87 and 6.4 among the incarcerated and Indigenous populations, compared with 33 the non-incarcerated and non-Indigenous populations respectively. We found significant 34 heterogeneity in TB incidence across Paraguay's 17 departments. Our findings highlight the 35 urgency of expanding access to TB diagnosis, treatment, and prevention in populations at 36 heightened risk of TB in Paraguay. 37 Funding 38 K01AI173385 (NIH, NIAID), University of Utah Undergraduate Research Opportunity Program 39 40 41 42 43

- 44
- 45
- 46

47

48 INTRODUCTION

49	Tuberculosis (TB) remains the leading cause of death from an infectious disease globally
50	(1). Despite being both preventable and curable, 1.3 million people died from TB in 2022 (1).
51	While over the past decade global incidence rates of TB have decreased, between 2015 and 2022
52	there was a 13% increase in TB incidence in the Americas (2,3). In Paraguay, a medium-
53	incidence country, the TB incidence increased from 42 (37-48) per 100,000 in 2010 (2) to 46
54	(39-54) per 100,000 in 2022 (4,5). Recently observed increases in TB notifications may partly
55	reflect the impact of the COVID-19 pandemic on TB case detection and treatment. Yet what
56	explains recent increases in the country's TB notifications and whether specific populations
57	remain at heightened risk of TB is not fully understood.
58	Globally, TB is a disease of poverty and is concentrated among populations marginalized
59	from access to healthcare and other social services. For example, incarcerated populations have
60	an incidence nine times that of the non-incarcerated population, and the relative risk of TB
61	among incarcerated populations is many times higher in some countries (6). This reflects
62	extreme overcrowding, lack of or limited access to healthcare, poor access to nutrition, and other
63	characteristics of carceral environments. In the Americas, Indigenous populations are also at
64	heightened risk for TB, reflecting historic and ongoing displacement and exclusion from access
65	to healthcare and other services (7,8). TB incidence among Indigenous peoples in South America
66	reached epidemic levels following European colonization (7), and has been amplified by social
67	marginalization, food insecurity, and a lack of access to housing and healthcare. While much of
68	Paraguay's Indigenous population lives in rural areas (9), similar barriers to TB diagnosis,
69	treatment, and broader healthcare exist among Indigenous communities residing in urban areas.

In Paraguay, a previous study found that the relative risk of TB in prisons compared to
the community was 70.3 (95% CI, 67.7-73.1) and an increasing percentage of country-wide TB
case notifications occurred among incarcerated individuals: 7.1% in 2009 and 14.5% in 2018 (5).
The result was a 250% increase in TB cases among the incarcerated population, from 2009 to
2018 (5).

75 The Indigenous population of Paraguay is another group with extremely high incidence 76 of TB, estimated to be 335.3 per 100,000 in 2016 (7). This incidence translates to a relative risk 77 of TB among Paraguay's Indigenous population of 9.3, the highest relative risk associated with 78 the Indigenous population among countries in the WHO Region of the Americas, three times higher than the next closest country (7). Additionally, over a quarter of Paraguay's population 79 80 falls below the national poverty line, potentially putting this group at heightened risk of TB (10). 81 Populations with heightened risk of TB in Paraguay have been identified in previous 82 studies (5,7), but updated estimates of relative risk of TB among these populations is needed, as 83 well as better understanding the spatial distribution of TB. Here, we analyzed TB notification 84 data from the Paraguay National Program for Tuberculosis Control (NPTC) from 2018-2022 to 85 identify populations with high incidence of TB that would benefit from increased access to TB prevention, diagnostics, and treatment. We identified populations and regions with high TB risk 86 87 and evaluated socioeconomic predictors of treatment failure.

88

89 METHODS

90 Country setting

91 There are 7.1 million inhabitants of Paraguay, of which two percent are Indigenous (9).
92 The country is divided by the Paraguay River into two main regions: the Eastern Region, which

is home to 97% of the population, and the Western Region (also known as the Paraguayan 93 94 Chaco), covering 61% of the national territory (14). The Western Region has a lower population 95 density, mainly comprised of Indigenous communities, which account for 30.1% of the region's 96 population and represent 45.6% of the national Indigenous population. The country is divided 97 into 17 departments. Asunción, the capital city, along with the Central Department, forms the 98 country's largest metropolitan area, including 37.6% of the national population (14). For this 99 study, we refer to Asunción as the area including both the Department of Asunción and Central 100 Department.

As recent estimates of the Indigenous population in each department were not available, we estimated department-level 2022 Indigenous populations using a linear model based on the official 2002 and 2012 census data to calculate department TB incidence among this population. All 17 prisons in Paraguay are located in the country's Eastern Region. A 2022 prison census identified 17,006 incarcerated individuals, 94.8% of whom are men. This represented 0.22% of the national population in 2022 (15).

107 NPTC Data Collection

Data on all TB patients were obtained from the NPTC database. As of 2018, the NPTC implemented the Tuberculosis Expert System (SEPNCT), which is a computer application component of the National Health Information System (SINAIS), intended to collect data related to suspected and confirmed cases of TB. The purpose of SEPNCT is to record and store information about patients, suspected cases, laboratory data, their treatments, monitoring, and contacts, for statistical, monitoring, surveillance, and notification purposes. For this study, we focused on TB cases reported from January 2018 to December 2022.

115 The database is dynamic, that is, annual data from specific years uploaded to SEPNCT are

116 continually updated and may change again in subsequent years. Socio-demographic variables 117 were taken from the NPTC registry (sex, age, residence) of all notified TB patients, including 118 those who belonged to TB risk groups under study, along with comorbidities, history of previous 119 tuberculosis treatment, clinical-epidemiological variables, and treatment results. Analysis and 120 data organization was completed in R (version 4.2.1) and R Studio (version 2023.03.1+446) 121

using the *tidyverse* packages (11).

122 Case Definitions

123 New TB cases were defined using the "history of previous treatment" variable. New 124 patients were defined as having never received treatment for TB or having previously received 125 treatment for less than one month. Previously treated patients were defined as having received 126 treatment for one month or longer. Previously treated patients are further classified by the results 127 of their most recent treatment cycle into: "Relapse," "Treatment after failure," "Treatment after 128 loss to follow-up," or "Other previously treated patients." Relapse is defined as a previously 129 treated patient, declared cured or treatment complete at the end of their last treatment cycle, and 130 who is diagnosed with a subsequent episode of TB whether due to reactivation or reinfection 131 (12,13). Treatment after failure refers to a patient with treatment failure at the end of their most recent treatment. Treatment after loss to follow-up refers to a patient declared lost to follow-up at 132 133 the end of their most recent treatment, previously known as abandonment. Other previously 134 treated patients are those previously treated, but with unknown or undocumented discharge 135 results after the most recent treatment. We defined notified cases to include both "New patients" 136 and "Relapsed patients." This included 13,725 of the 15,025 total reported cases (91.3%). 137 The NPTC defines a person deprived of liberty as an individual who is reported to be 138 incarcerated at the time of notification of the diagnosis of TB. Membership in an Indigenous

population is self-reported to the NPTC. Indigenous and incarcerated population variables had no
missing data, and only the responses "Yes" or "No." The incarcerated population variable was
cross checked with a "Penitentiary" binary variable (reporting if the patient was in a penitentiary)
to ensure completeness.

Treatment success was determined using the "treatment result" variable. Patients reported as "cured" and "completed treatment" were considered to have successful treatment. Patients were considered cured if they completed treatment as recommended by national policy without evidence of failure and possessed three or more consecutive negative cultures with an interval of at least 30 days between them. Patients were recorded as having completed treatment if they had completed treatment as recommended by national policy without evidence of three or more consecutive negative cultures of failure, but without evidence of three or more consecutive negative cultures at least 30 days apart.

150 Mapping

151 Mapping was completed in R using the packages sf(16) and ggplot2 (17). Paraguay 152 department level shape files were obtained from the Paraguay – Subnational Administrative 153 Boundaries dataset provided by the UN Office for the Coordination of Humanitarian Affairs 154 "Humanitarian Data Exchange (18)." Map population data was determined by the "department of residence" category in the NPTC database, which reflects the home address that the patient 155 156 provides. This is also adjusted in the information system, in case the patient moves, so they can 157 receive their medication. This information is kept up to date in SEPNCT. All incident case 158 observations had a listed department of residence. 5 of the 13,725 incident cases (0.04%) had a 159 department of residence listed as "Foreign." These five cases were excluded in population totals 160 for mapping. General population data for mapping was obtained from the "Projection of the 161 National Population" data provided by the Paraguay National Institute of Statistics (19).

162 Statistical Analysis

Statistical analysis was carried out using R. T-tests and chi-square tests were performed 163 164 using the *stats* package (20). Adjusted odds ratios were obtained from a linear model produced 165 with the *glm* function from the stats package (20). Risk ratios for the incarcerated and Indigenous 166 individuals were calculated with 2022 case notifications, and population data from the Paraguay 167 National Institute of Statistics (19). We tested the effect on treatment outcome of clinical and 168 sociodemographic variables in a multivariable logistic regression model that included age, 169 gender, education level, year of case diagnosis, incarceration status, enrollment in directly observed therapy (DOT), self-reported Indigenous population status, diabetes, alcohol use 170 171 disorder, mental disorder, HIV status, possession of a GeneXpert test result, and an interaction 172 term between incarceration status and DOT. A total of 12% of notified cases had a treatment 173 result that was either missing or in progress. These notifications were excluded in the linear 174 model. An additional 43 cases were reported to be positive for rifampin resistance and were also 175 excluded from treatment outcome analysis. 176 Ethics Statement

177 This study was approved by the IRB at the University of Utah (IRB_00167535) and by178 the Instituto de Medicina Tropical, Asunción, Paraguay.

179

180 **RESULTS**

From 2018-2022, a total of 13,725 incident TB cases were reported by the National Program for Tuberculosis Control (NPTC) in Paraguay. Countrywide case notification rates remained constant over this five-year period at approximately 46 cases per 100,000 (χ^2 test,

p=0.78). Of the 13,725 total reported TB cases, 1,743 (12.7%) were among the Indigenous
population and 2,331 (17%) were among the incarcerated population.

We found significant variation in case notification across individual departments (χ^2 test, 186 187 p<0.001) and variation in trends over time. Over the 5-year study period, the highest increase in 188 notification was in Boquerón, where case notifications rose from 118.2 per 100,000 in 2018 to 189 157.3 per 100,000 in 2022 (Fig. 1). Other departments that experienced notable increases were 190 Concepción (an increase of 94.5%), Amambay (63.0%), and Cordillera (63.1%). The greatest 191 decrease in notifications was in Alto Paraguay, where case notifications decreased from 96.9 per 192 100,000 in 2018 to 73.9 per 100,000 in 2022. Boquerón and Alto Paraguay are both departments 193 in the Chaco with a high proportion of Indigenous residents, 43.4% and 25.1%, respectively. In 194 total, 45% of TB cases (787 out of 1,743) among the Indigenous population were located in the 195 Chaco Region (Fig. 2). Among the TB cases in the Chaco, approximately 75% (787 out of 1,048) 196 were among individuals identifying as Indigenous.

We observed significant variation in TB notifications in the Indigenous population across
space. Asunción has the highest notification rate among the Indigenous population of 1127.4
cases per 100,000 in 2022 (Fig. 3). Other departments also had high notification rates: 793.7
cases per 100,000 in Guairá and 493.8 cases per 100,000 in Itapúa in 2022. In 2022 Paraguay's
Indigenous populations had a relative risk of TB notification 6.4 times higher than the nonIndigenous population.

Among the Indigenous population, 54.4% (948 out of 1743) of reported cases occurred in men. The proportion of individuals with TB who were HIV co-infected was lower among the Indigenous population than the non-Indigenous population (1.7% vs 7.6%, p<0.001). Individuals

206 diagnosed with TB who are Indigenous had a lower median age than their non-Indigenous
207 counterparts (32 years vs. 35 years, p<0.001).

208 2,331 of the 13,725 reported TB cases (17%) were among the incarcerated population. 209 The departments with the highest proportion of cases among the incarcerated population were 210 Cordillera (55.4%, 456 of 823) and Misiones (44.2%, 91 of 206). TB cases among the 211 incarcerated population occur in the Eastern Region, where all Paraguay's prisons are located 212 (Fig. 2). The majority of cases notified among the incarcerated population occurred in men, 98.9%, compared with 67.1% in the general population (χ^2 test, p<0.001). The proportion of 213 214 individuals with TB who were HIV co-infected was lower among the incarcerated population 215 than the general population (3.5% vs 7.6%, p<0.001). The median age of incarcerated individuals 216 with TB was lower (28 vs. 35, p<0.001) and people who are incarcerated were more likely to be 217 treated under DOT (88.7% vs 53.6%, p<0.001) than non-incarcerated individuals with TB. In 218 2022, Paraguay's incarcerated population had a relative risk of TB notification 87 times higher 219 than the non-incarcerated population.

220 Rapid molecular tests, including GeneXpert, are the recommended diagnostic test for TB 221 diagnosis (21). From 2018-2022, GeneXpert usage for diagnosing incident cases of TB increased 222 from 23% in 2018 to 72% in 2022 (t-test; p<0.001), and a pattern of increase was observed 223 across subpopulations (Fig. 4). From 2018-2022, the proportion of TB cases diagnosed with 224 GeneXpert among the Indigenous population was slightly lower than that diagnosed using 225 GeneXpert among the non-incarcerated, non-Indigenous population (35.4% vs. 37.0%, p<0.001). 226 TB cases among the incarcerated population were diagnosed using GeneXpert at a higher rate 227 than the non-incarcerated, non-Indigenous population (55.3% vs. 37.0%, p<0.001).

Of the 13,725 notified TB cases recorded by the Paraguay NPTC from 2018-2022, 8,238 (60%) had successful treatment, 2,240 (16%) were lost to follow up, 1,451 (11%) died, 85 (0.6%) reported treatment failure, 1,293 (9%) reported treatment still in progress, and 418 (3%) were missing data.

232 In a multiple linear regression model (Table 2), DOT (Directly Observed Therapy) (aOR: 233 1.66; 95% CI: 1.51, 1.84), diabetes (aOR: 1.39; 95% CI: 1.17-1.66), being a member of the 234 Indigenous population (aOR: 1.41; 95% CI: 1.21-1.66), and Tertiary/University level education 235 (aOR: 3.68; 95% CI: 2.85-4.78) were positively associated with treatment success for drug-236 susceptible TB. While incarceration alone was not significantly associated with positive or 237 negative treatment success (aOR: 1.15; 95% CI: 0.81–1.64), an interaction term between DOT 238 and incarceration was positively associated with successful treatment (aOR: 2.51; 95% CI: 1.69-239 3.70). Factors negatively associated with treatment success included co-infection with HIV 240 (aOR: 0.20; 95% CI: 0.17-0.23), Alcohol Use Disorder (aOR: 0.70; 95% CI: 0.59-0.84), and age 241 over 65 (aOR: 0.42; 95% CI: 0.34-0.51).

242

243 **DISCUSSION**

Despite advances in diagnosis and treatment, TB remains a significant public health threat in Paraguay, with a disproportionate impact among populations marginalized from healthcare, including Indigenous people and incarcerated individuals. In this retrospective study conducted between 2018 and 2022, based on NPTC data, we found that TB case notifications are concentrated spatially and within specific subpopulations.

Paraguay's Indigenous population continues to have an exorbitantly high relative risk of
TB. Our findings confirm that the Chaco Region, the region home to the majority of Paraguay's

Indigenous population, has the highest incidence of TB in the country. In 2017, members of the Pan American Health Association developed a shared set of guidelines to improve Indigenous health, including reducing the burden of TB (7). Since 2019, the NPTC has expanded access to diagnostics and treatment and treatment support programs for Indigenous populations, which may be responsible for the improvements in treatment success we observe here.

256 The TB epidemic in Paraguay is also increasingly concentrated in prisons, where the 257 incidence of TB among the incarcerated population remains a major health justice issue. Most 258 TB cases among the incarcerated population are located in the eastern part of the country, 259 including the departments of Cordillera and Misiones. We found that while the use of DOT 260 increases odds of treatment success for everyone, it is particularly important for the incarcerated 261 population. This is consistent with a study in Brazil, where DOT access was associated with 262 greater improvements in treatment outcomes among incarcerated individuals compared to the 263 non-incarcerated population (22). Recently, the NPTC has implemented TB programs in 264 penitentiary centers that aim to provide universal DOT. Our findings emphasize the broad 265 importance of access to DOT, and the need for its continued expansion within populations with 266 the highest incidence of TB.

Paraguay was one of the first countries in the WHO Americas Region to adopt molecular rapid tests for initial TB diagnosis. As of October 2020, GeneXpert testing replaced sputum microscopy as the initial TB diagnostic. Previously, GeneXpert testing was applied as part of targeted recommendations for groups with high incidence, including incarcerated individuals. We found significant increases in GeneXpert use country-wide, including in incarcerated and Indigenous populations. Historically, access to TB diagnostics was limited in the Chaco, leading to what was likely a large burden of undiagnosed TB. We found that all case notifications among

the Indigenous population in Alto Paraguay, one of the three departments in the Chaco, possesseda GeneXpert testing result.

276 We expect that the ongoing expansion of GeneXpert testing will continue to improve case 277 detection rates, critical for both improving TB treatment outcomes and reducing transmission. 278 We found that rates of access to GeneXpert testing availability among the Indigenous population 279 lag behind the non-Indigenous population, highlighting the need to prioritize the expansion of 280 diagnostics to this population in both the Chaco Region and the urban Indigenous population in 281 the Central Department, which has the highest incidence rate among Indigenous peoples. 282 Our analysis was made possible by the detailed data provided by the NPTC. 283 Comprehensive data that was geographically tracked and connected to sociodemographic 284 indicators provides valuable insight into TB trends over time. Additionally, it allows for spatially 285 informed analysis that guides effective interventions to areas of high need. 286 Our study has several limitations. Our analysis of incidence rates among the Indigenous 287 population relied on Indigenous population data. At the time of analysis, the last official census 288 data including Indigenous population data was from 2012. To calculate 2022 incidence rates, we 289 used linear regression to estimate the 2022 Indigenous population data using the official 2002 290 and 2012 census data.

Further, we were unable to examine the spatial distribution of TB cases at a resolution higher than department-level because of missing information in the TB registry. However, we were still able to identify meaningful spatial patterns. Additionally, the TB registry lacked information about prior incarceration. Incarceration history is a major risk factor for TB and it is possible that many cases that were notified among non-incarcerated individuals occurred among individuals with recent incarceration. Lastly, working with reported case data presents the

297	challenge that we cannot estimate unreported cases. Unreported cases may occur
298	disproportionately among vulnerable populations, leading us to underestimate incidence rates.
299	TB remains a major public health problem in Paraguay, with a burden that is concentrated
300	among vulnerable populations. Our study highlights the benefit of expanding molecular TB
301	testing across the country and highlights areas and populations that could benefit from continued
302	expansion of molecular testing. We also found that DOT treatment continues to be a critical
303	component of treatment regimes, particularly for incarcerated populations. Together, these
304	findings highlight the urgency in supporting public health programs to improve the diagnosis,
305	treatment, and prevention of TB among groups historically marginalized from health and social
306	services to reduce the exceedingly high burden of TB.
307	
308	
309	
310	
311	
312	
313	
314	
315	
316	
317	
318	
319	





Figure 1: Tuberculosis Notifications in Paraguay 2018-2022

- 325 TB notifications per 100,000 in Paraguay by department in (A) 2018 and (B) 2022.
- 326 (C) Difference from 2018 to 2022 in tuberculosis notification per 100,000 by department.





343 Incarcerated Populations

- Proportion of reported tuberculosis cases by department that indicated being a member of an
 Indigenous group in (A) 2018, (C) 2022, and that are incarcerated in (B) 2018, (D) 2022.



355

356 *Figure 3:* Tuberculosis Among Paraguay's Vulnerable Populations in 2022

(A) 2022 TB notifications per 100,000 among the Indigenous population (departments in grey
 had no reported Indigenous residents), and (B) 2022 TB notifications and population size of
 major prison facilities¹.

360

¹ San Juan Bautista was excluded due to unavailable population data



Figure 4: GeneXpert Testing Usage in Paraguay, 2018-2022

Proportion of tuberculosis cases in Paraguay with a GeneXpert result by department in 2018 (A),
and 2022 (B). (C) Proportion of tuberculosis cases in Paraguay with a GeneXpert result divided

- 366 by subpopulation from 2018 to 2022.

376

Table 1. Sociodemographic characteristics for new TB case notifications 2018-2022, by incarcerated and Indigenous status

379

			No. (%)*	
Variable	Category	Total	Incarcerated	Indigenous
		n = 13,725	n = 2,331	n = 1,743
Age				
	< 18	1,282 (9.3)	13 (0.6)	349 (20.0)
	18-25	2,525 (18.4)	818 (35.1)	283 (16.2)
	26-45	5,416 (39.5)	1,346 (57.7)	540 31.0)
	46-65	3,087 (22.5)	145 (6.2)	351 (20.1)
	> 65	1,415 (10.3)	9 (0.4)	220 (12.6)
Gender				
	Female	3,770 (27.5)	26 (1.1)	795 (45.6)
	Male	9,955 (72.5)	2,305 (98.9)	948 (54.4)
Comorbidity				
	HIV	945 (6.8)	81 (3.5)	29 (1.7)
	Diabetes	1,132 (8.2)	39 (1.7)	54 (3.1)
	Alcohol use	994 (7.2)	394 (16.9)	55 (3.2)
	Drug resistance	53 (0.4)	8 (0.3)	11 (0.6)
Education				
	None	1,569 (11.4)	135 (5.8)	726 (41.7)
	Basic	4,659 (33.9)	1,015 (43.5)	351 (20.1)
	Initial	2,140 (15.6)	371 (15.9)	346 (19.9)
	Medium Level	2,175 (15.8)	317 (13.6)	39 (2.2)
	Tertiary/University	708 (5.2)	10 (0.4)	8 (0.5)
	N/A	2,474 (18.0)	483 (20.7)	273 (15.7)
DOT		8,178 (59.6)	2,067 (88.7)	1,101 (63.2)
Treatment		8 238 (60 0)	1 656 (71 0)	1 114 (64 0)
Success		8,238 (00.0)	1,030 (71.0)	1,114 (04.0)
Year				
	2018	2,576 (18.8)	408 (17.5)	315 (18.1)
	2019	2,824 (20.6)	417 (17.9)	363 (20.8)
	2020	2,358 (17.2)	374 (16.0)	303 (17.4)
	2021	2,717 (19.8)	515 (22.1)	337 (19.3)
	2022	3,250 (23.7)	617 (26.5)	425 (24.4)

380 *Percentage calculated as number in category listed divided by total notifications in specified

381 group.

382

383

384

385

- _ _ _
- **Table 2.** Adjusted odds ratios for treatment success among all newly diagnosed Tuberculosis
- 391 cases using multiple linear regression

Adjusted Odds Ratio (95% CI)
1.66 (1.51 – 1.84)
1.15 (0.81 – 1.64)
$1*DOT^2$ 2.51 (1.69 – 3.70)
0.20 (0.17 – 0.23)
1.39 (1.17 – 1.66)
Disorder $0.70 (0.59 - 0.84)$
1.41 (1.21 – 1.66)
Referent
0.62(0.50-0.75)
0.66(0.55 - 0.79)
0.63 (0.52 – 0.76)
0.42(0.34 - 0.51)
Referent
1.65 (1.42 – 1.92)
1.87 (1.58 – 2.21)
el $2.05 (1.72 - 2.44)$
versity 3.68 (2.85 – 4.78)
Ň

² Incarceration*DOT indicates the use of an interaction term

403	
404	
405	
406	
407	
408	
409	
410	References
411	
412	1. Geneva: World Health Organization. Global Tuberculosis Report 2022. [Internet]. Geneva,
413	Switzerland. 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-
414	reports/global-tuberculosis-report-2022
415	2. Situation of Tuberculosis in the Americas. Pan American Health Organization. [Internet].
416	2023. https://www.paho.org/en/topics/tuberculosis/situation-tuberculosis-americas
417	3. Tuberculosis in the Americas - Regional Report 2021[in Spanish]. Organización Panamericana
418	de la Salud. Washington, D.C.; 2022.
419	https://iris.paho.org/bitstream/handle/10665.2/57084/9789275326497_spa.pdf?sequence=
420	11&isAllowed=y
421	4. World Health Organization Global Tuberculosis Programme. Tuberculosis profile: Paraguay.
422	[Internet]. Shiny App. Generated February 2024. Geneva, Switzerland.
423	https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22
424	&1so2=%22PY%22&lan=%22EN%22
425	5. Sequera VG, Aguirre S, Estigarribia G, Cellamare M, Croda J, Andrews JR, et al. Increased
426	tak analysis control in Processor Sci Par. 2020;10(1)
427	tuberculosis control in Paraguay. Sci Kep. 2020;10(1).
428	o. Martinez L, Warren JL, Harres AD, Croua J, Espiriar MA, Orarte KAL, et al. Global, regional,
429	individuals from 2000 to 2010; a systematic analysis. Langet Dublic Health, 2022;8(7)
450	7 Guidelines for the Prevention and Control of Tuberculosis in the Indigenous Peoples of the
431 422	Pagion of the Americas [in Spanish] Organización Denemoricana de la Salud [Internet]
432 122	We shington $DC \cdot 2020$
433	https://iris.paho.org/bitstream/handle/10665.2/53308/0780275322772_spa.pdf?sequence-
434 135	1 & s Allowed-v
436	8 Tollefson D Bloss F Fanning A Redd IT Barker K McCray F Burden of tuberculosis in
437	indigenous peoples globally: A systematic review International Journal of Tuberculosis
438	and Lung Disease 2013.17(9)
439	9 Land and Territory Foundations of Life for Indigenous Peoples 2012 [in Spanish] La
440	Dirección General de Estadística. Encuestas y Censos. [Internet]. Fernando de la Mora
441	Paraguay, 2016.
442	https://www.ine.gov.pv/Publicaciones/Biblioteca/documento/0b43_Tierra%20v%20territ
443	orio.%20Fundamentos%20de%20vida%20de%20los%20pueblos%20indigenas.pdf
444	10. Sanabria GE, Sequera G, Aguirre S, Méndez J, dos Santos PCP, Gustafson NW. et al.
445	Phylogeography and transmission of Mycobacterium tuberculosis spanning prisons and
446	surrounding communities in Paraguay. Nat Commun. 2023;14(1).

- 447 11. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. "Welcome to 448 the tidyverse." Journal of Open Source Software. 2019. 449 https://doi.org/10.21105/joss.01686. 450 12. Paraguay Programa Nacional de Control de Tuberculosis. National Guide for Tuberculosis 451 Management [in Spanish]. [Internet]. Ministerio de Salud Pública y Bienestar Social. 452 15th Ediction. 2018. https://dgvs.mspbs.gov.py/wp-453 content/uploads/2022/12/guia nacional tb interior 2018 compressed.pdf 454 13. Definitions and Framework for Tuberculosis Reporting - 2013 Review [in Spanish]. 455 Organización Mundial de la Salud. [Internet]. Geneva, Switzerland. 2013. 456 https://www3.paho.org/hq/dmdocuments/2013/PAHO-definiciones-marco-TB-2013-Spa-457 1.pdf 458 14. Total Population by Calendar Year, by Sex and Department, 2000-2025 [in Spanish]. 459 [Internet]. Instituto Nacional de Estadística Paraguay. 2023. 460 https://www.ine.gov.py/publicacion/2/poblacion 461 15. World Prison Brief data. Paraguay. [Internet]. World Prison Brief, Institute for Crime & 462 Justice Policy Research. 2023. https://www.prisonstudies.org/country/paraguay 16. Pebesma, E., 2018. Simple Features for R: Standardized Support for Spatial Vector Data. The 463 464 R Journal 10 (1), 439-446, https://doi.org/10.32614/RJ-2018-009. 465 17. H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2016. 18. United Nations Office for the Coordination of Humanitarian Affairs. Paraguay - Subnational 466 467 Administrative Boundaries. [Internet]. Humanitarian Data Exchange. September 2020 468 update. https://data.humdata.org/dataset/cod-ab-pry? 469 19. Projection of National Population, Urban and Rural Areas by Sex and Age, 2000-2025. 2015 470 Revision [in Spanish]. [Internet]. Instituto Nacional de Estadística Paraguay. 2023. 471 https://www.ine.gov.py/publicacion/2/poblacion 20. R Core Team (2022). R: A language and environment for statistical computing. R Foundation 472 473 for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. 474 21. Geneva: World Health Organization. WHO consolidated guidelines on tuberculosis. Module 475 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. [Internet]. 476 Geneva, Switzerland. 2021. https://iris.who.int/bitstream/handle/10665/342331/9789240029415-eng.pdf?sequence=1 477 478 22. O'Marr JM, Gonçalves C, Arakaki-Sanchez D, Pelissari DM, Costa FD, Croda J, et al. The
- 479 effect of incarceration on TB treatment outcomes. International Journal of Tuberculosis and Lung
- 480 Disease. 2022;26(3).
- 481